Doxorubicin HS Code Analysis (2026)

Doxorubicin is primarily classified under HS code 30049046, which pertains to "Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses or in forms or packings for retail sale." The Most Favored Nation (MFN) tariff rates and preferential rates under Free Trade Agreements (FTAs) for this HS code vary across key importing countries:

• United States: The MFN tariff rate for HS code 30049046 is 0%. Under the United States-Mexico-Canada Agreement (USMCA), preferential rates may apply to qualifying products. Additionally, certain essential medicines may be exempt from tariffs under specific provisions.

• Canada: According to the Canada Border Services Agency (CBSA), Canada applies an MFN tariff rate of 0% for HS code 30049046. As a member of the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP), Canada offers preferential rates to member countries, including India. Essential medicines may also benefit from tariff exemptions under Canadian regulations. (cbsa-asfc.gc.ca)

• Australia: Australia's MFN tariff rate for HS code 30049046 is 0%. Under the Australia-India Comprehensive Economic Cooperation Agreement (CECA), preferential rates may be available for qualifying products. Essential medicines are often exempt from tariffs to ensure public health access.

• Vietnam: Vietnam applies an MFN tariff rate of 0% for HS code 30049046. As a member of the ASEAN-India Free Trade Area (AIFTA), Vietnam offers preferential rates to Indian exports. Essential medicines may be subject to tariff exemptions under Vietnamese law.

• Saudi Arabia: Saudi Arabia's MFN tariff rate for HS code 30049046 is 0%. While there is no specific FTA between Saudi Arabia and India, essential medicines may be exempt from tariffs under Saudi regulations to promote healthcare access.

• Thailand: Thailand applies an MFN tariff rate of 0% for HS code 30049046. Under the ASEAN-India Free Trade Area (AIFTA), Thailand offers preferential rates to Indian exports. Essential medicines may benefit from tariff exemptions under Thai law.

• Colombia: Colombia's MFN tariff rate for HS code 30049046 is 0%. Under the India-Colombia Preferential Trade Agreement, preferential rates may be available for qualifying products. Essential medicines are often exempt from tariffs to ensure public health access.

• Mozambique: Mozambique applies an MFN tariff rate of 0% for HS code 30049046. As a Least Developed Country (LDC), Mozambique may offer preferential rates to Indian exports under the Duty-Free Tariff Preference (DFTP) scheme. Essential medicines are typically exempt from tariffs to promote healthcare access.

Doxorubicin can be classified under HS code 3003 or 3004, depending on its form and packaging:

• HS Code 3003: Applies to medicaments consisting of two or more constituents mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale.

• HS Code 3004: Applies to medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses or in forms or packings for retail sale.

Common misclassification errors include:

• Incorrect Classification under HS 3003: Classifying Doxorubicin preparations intended for retail sale under HS 3003 instead of HS 3004.

• Use of Non-Specific Codes: Utilizing generic codes like 30049099 instead of the more specific 30049046, leading to inaccuracies in trade data and potential compliance issues.

Customs authorities may impose penalties for misclassification, including fines and delays in shipment clearance. Recent rulings by the World Customs Organization (WCO) and national customs authorities emphasize the importance of accurate classification to ensure proper duty assessment and compliance with trade regulations.

Doxorubicin is recognized in several major pharmacopoeias, each specifying quality standards to ensure its safety and efficacy:

• United States Pharmacopeia (USP): The USP monograph for Doxorubicin Hydrochloride Injection defines it as a sterile solution containing not less than 90.0% and not more than 115.0% of the labeled amount of doxorubicin hydrochloride.

• British Pharmacopoeia (BP) and European Pharmacopoeia (EP): These pharmacopoeias include monographs for Doxorubicin, detailing specifications for purity, assay, and other quality parameters.

• Indian Pharmacopoeia (IP): The IP monograph for Doxorubicin outlines quality standards, including purity and assay requirements, to ensure the drug's safety and efficacy.

Key quality parameters across these pharmacopoeias include:

• Purity/Assay Requirements: Ensuring the active pharmaceutical ingredient (API) meets specified purity levels and contains the correct amount of active substance.

• Dissolution Testing: Assessing the rate and extent of drug release from the dosage form, which is crucial for bioavailability. The USP provides guidelines for dissolution testing in general chapters such as <711> Dissolution.

• Stability Testing: Conducted according to the International Council for Harmonisation (ICH) guidelines, stability testing evaluates how the quality of a drug substance or product varies with time under the influence of environmental factors such as temperature, humidity, and light. This ensures that Doxorubicin maintains its intended quality throughout its shelf life.

Adherence to these pharmacopoeial standards is essential for regulatory compliance and to ensure the therapeutic efficacy and safety of Doxorubicin products in the market.